China Resources Double-Crane Pharmaceutical (600062.SH): Isavuconazonium Sulfate for Injection and Others Obtain Drug Registration Certificates

China Resources Double-Crane Pharmaceutical (600062.SH) announced that recently, the company, its wholly-owned subsidiary Xi'an Jingxi Shuanghe Pharmaceutical Co., Ltd., and its controlled subsidiary China Resources Double-Crane Pharmaceutical Xiangzhong Pharmaceutical (Hunan) Co., Ltd. respectively received the Drug Registration Certificates issued by the National Medical Products Administration for Isavuconazonium Sulfate for Injection, Sorbitol Mannitol Irrigation Solution, and Brexpiprazole Tablets. It is reported that Isavuconazonium Sulfate for Injection is indicated for the treatment of the following infections in adult and pediatric patients aged 1 year and older: invasive aspergillosis and invasive mucormycosis. Sorbitol Mannitol Irrigation Solution is indicated for intraoperative irrigation during transurethral resection of the prostate and other urological surgeries. Brexpiprazole Tablets are indicated for the treatment of schizophrenia in adults. The obtaining of the Drug Registration Certificates for Isavuconazonium Sulfate for Injection, Sorbitol Mannitol Irrigation Solution, and Brexpiprazole Tablets will further enrich the company's product portfolio, help enhance the market competitiveness of the company's products, and accumulate valuable experience for the subsequent research and development of other products.